[December 28, 2020]
Junshi Biosciences Announces Inclusion of Toripalimab in The China National Reimbursement Drug List
SHANGHAI, China, Dec. 29, 2020 (GLOBE NEWSWIRE) Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, is pleased to announce that toripalimab has been included in the updated National Reimbursement Drug List (NRDL) (2020 Edition) for the treatment of melanoma by the China National Healthcare Security Administration (NHSA). The primary drug format specification is the 80mg(2ml)/vial. Toripalimab is the only anti-PD-1 monoclonal antibody for the treatment of melanoma that has been included in the NRDL.
Melanoma is an aggressive form of solid tumor with a rapid systemic dissemination. Toripalimab received a conditional approval by the NMPA for the 2
Investegate |Junshi Biosciences Announcements | Junshi Biosciences: CHOICE-01 Phase III Study of Toripalimab at the Interim Analysis Met Pre-Specified Primary Endpoint of Progression-Free Survival at the First-Line Treatment of Advanced NSCLC
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
CHOICE-01 Phase III Study of Toripalimab at the Interim Analysis Met Pre-Specified Primary Endpoint of Progression-Free Survival at the First-Line Treatment of Advanced NSCLC – IT Business Net
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
CHOICE-01 Phase III Study of Toripalimab at the Interim Analysis Met Pre-Specified Primary Endpoint of Progression-Free Survival at the First-Line Treatment of Advanced NSCLC
December 13, 2020 19:00 ET | Source: Junshi Biosciences Junshi Biosciences Shanghai, CHINA
SHANGHAI, China, Dec. 14, 2020 (GLOBE NEWSWIRE) Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, is pleased to announce that the Independent Data Monitoring Committee (IDMC) has determined that Toripalimab (product code: JS001) in combination with standard chemotherapy as the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) has reached its pre-specified primary endpoint of Progression Free Survival (PFS) at the interim analysis of a randomized, double-blind, multi-center, phase III clinical study “CHOICE-01